Edgestream Partners, L.P. Biomarin Pharmaceutical Inc Transaction History
Edgestream Partners, L.P.
- $2.29 Billion
- Q4 2024
A detailed history of Edgestream Partners, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 144,996 shares of BMRN stock, worth $9.4 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
144,996
Previous 28,562
407.65%
Holding current value
$9.4 Million
Previous $2.01 Million
374.84%
% of portfolio
0.42%
Previous 0.09%
Shares
8 transactions
Others Institutions Holding BMRN
# of Institutions
630Shares Held
183MCall Options Held
2MPut Options Held
1.72M-
Black Rock Inc. New York, NY22.7MShares$1.47 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.26 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.18 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$956 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$843 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...